C. Boyd Clarke

Executive Chairman at FluGen, Inc.

C. Boyd Clarke

C. Boyd Clarke

Executive Chairman at FluGen, Inc.

Overview
Career Highlights

Pasteur Merieux MSD Ltd.
FluGen, Inc.
LigoCyte Pharmaceuticals, Inc.

RelSci Relationships

730

Number of Boards

13

Birthday

1950

Age

71

Contact Data
Trying to get in touch with C. Boyd Clarke? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals C. Boyd Clarke likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Medical Officer at Allena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at FluGen, Inc.

Relationship likelihood: Strong

General Counsel & Secretary at Optivia Biotechnology, Inc.

Relationship likelihood: Strong

Former Executive Chairman at Infectious Disease Research Institute

Relationship likelihood: Strong

Chief Executive Officer, President & Director at Aldeyra Therapeutics, Inc.

Relationship likelihood: Strong

Former President, Chief Executive Officer & Director at StemCells, Inc.

Relationship likelihood: Strong

Director & Co-Founder at FluGen, Inc.

Relationship likelihood: Strong

Chief Scientific Officer at Infectious Disease Research Institute

Relationship likelihood: Strong

Former Executive Chairman at Envisia Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Mati Therapeutics, Inc.

Relationship likelihood: Strong

Paths to C. Boyd Clarke
Potential Connections via
Relationship Science
You
C. Boyd Clarke
Executive Chairman at FluGen, Inc.
Education
Master of Arts in History

The University of Calgary (or UCalgary) is a public research university located in Calgary, Alberta, Canada. Founded in 1966 (after operating as the Calgary branch of the University of Alberta since 1945) the University of Calgary is composed of 14 faculties and more than 85 research institutes and centres.

Career History
Executive Chairman
Current

Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology.The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI.

Venture Advisor
2007 - Prior

ProQuest Management invests in healthcare companies located in the US. The sectors in which they invest include biotech and pharmaceutical companies. The firm provides financing for seed to late-stage capital requirements and the firm invests in both public & private companies.

President & Chief Executive Officer
2002 - 2007

The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.

Boards & Committees
Chairman
2003 - 2012

QLT is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. QLT's head office is based in Vancouver, Canada and the company is publicly traded on NASDAQ (symbol: QLTI) and the Toronto Stock Exchange (symbol: QLT).

Chairman
Prior

MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA

Director
Prior

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Transactions
Details Hidden

LigoCyte Pharmaceuticals, Inc. raised money in a private placement transaction

Investments
Details Hidden

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by C. Boyd Clarke. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of C. Boyd Clarke's profile does not indicate a business or promotional relationship of any kind between RelSci and C. Boyd Clarke.